Lilly Asia Ventures
China's Lynk Pharmaceutical increases Series C to $44m
China-based drug developer Lynk Pharmaceuticals has closed a second tranche of Series C funding, taking the overall size of the round to CNY 322m (USD 44m).
China robot surgery specialist raises $27m
Shanghai-based surgical robot business Ronovo Surgical has raised CNY200m（USD 27m）in an extended pre-Series B round led by NRL Capital.
China's Leadsynbio raises Series D
Chinese synthetic biology company Leadsynbio has raised a Series D round of unspecified size from existing investors Lilly Asia Ventures and Sherpa Healthcare Partners.
China’s Cornerstone Robotics raises $112m
China-based Cornerstone Robotics, a surgical robots specialist, has raised a CNY 800m (USD 112m) round featuring BridgeOne Capital and Lenovo Capital & Incubator Group.
SDIC leads $97m Series A for China's Pyrotech Therapeutics
China-based Pyrotech Therapeutics, which develops treatments for inflammation and tumours, has raised a Series A of CNY 700m (USD 97m) led by state-owned investor SDIC Venture Capital.
China's Alebund Pharma gets $145m in debt, equity funding
Alebund Pharmaceuticals has raised close to CNY 200m (USD 29m) in a pre-Series C funding round. Investors include state-owned Yangzhou Guojin Investment and Yangzhou Longchuan Holdings.
China GPs re-up in ArriVent Biopharma's $155m Series B
Assorted Chinese investors have participated in a USD 155m Series B round for US-headquartered ArriVent Biopharma, which targets drug candidates emanating from emerging biotech hubs, including China.
Cenova leads $40m Series B for China's Eluminex
China-based healthcare investor Cenova Capital has led a USD 40m Series B round for Eluminex Biosciences, which is developing drugs and regenerative tissue used to treat eye disease and other vision-threatening medical conditions.
China medical devices manufacturer LavaMed raises $40m
SuZhou LavaMed, a China-based medical devices manufacturer, has raised USD 40m in angel and Series A funding from Zhejiang Silk Road Fund, Junshang Capital, and Lilly Asia Ventures (LAV).
China cell therapy developer Neukio raises $50m
Shanghai-based cell therapy developer Neukio Biotherapeutics has raised USD 50m in the first tranche of a Series A round led by medical technology-focused CD Capital. Other new investors include Alwin Capital and Surplus Capital.
China biotech company GluBio raises $22m
China and US-based GluBio Therapeutics, which develops targeted protein degradation (TPD) drugs, has raised an extended Series A round of USD22m led by Qiming Venture Partners.
Legend leads $150m Series E for China CRO ClinChoice
US and China-based clinical contract research organization (CRO) company ClinChoice has raised a USD 150m Series E round led by Legend Capital.
Fengshi leads $45m Series D for China cancer diagnosis player
Singlera Genomics, a Shanghai-based cancer diagnostics specialist, has raised an extended Series B round of CNY 300m (USD 45m) led by Fengshi Investment Management.
Sequoia leads Series A extension for China's ProfoundBio
Sequoia Capital China has led a USD 70m extended Series A round for ProfoundBio, a Chinese drug developer with two cancer treatments entering phase-one clinical trials.
Singapore's Virtue Diagnostics closes $100m Series B
Singapore-based Virtue Diagnostics, a clinical testing equipment supplier for China and developing markets, has raised a USD 100m Series B round led by Sequoia Capital China and Morningside Ventures.
China CRO Tripod raises $156m
Tripod Preclinical Research Laboratories, a China-based contract research organization (CRO) based in Nanjing, has raised RMB1 billion ($156 million) led by Ruihua Capital, Lilly Asia Ventures (LAV) and GL Ventures.
PE-backed Abbisko trades up after $225m Hong Kong IPO
China-based oncology drug developer Abbisko Therapeutics gained nearly 10% on its Hong Kong trading debut following a HK$1.75 billion ($225 million) IPO.
PE-backed MicroTech Medical targets $254m Hong Kong IPO
MicroTech Medical, a China-based manufacturer of insulin pumps for diabetes sufferers that counts Lilly Asia Ventures (LAV) and Qiming Venture Partners among its investors, is looking to raise up to HK$1.98 billion ($254 million) in a Hong Kong IPO.
LAV leads $50m Series B for China's Lynk Pharma
Lilly Asia Ventures (LAV) has led a $50 million Series B round for Lynk Pharmaceuticals, a China-based drug developer that focuses on small-molecule treatments for autoimmune disease, inflammation, and cancer.
China cancer treatment specialist Ionova raises $100m
Tsing Song Capital, a Chinese healthcare-focused private equity firm, has led a $100 million round for Ionova Life Science, a local biotech player specializing in cancer treatments.
China vaccine developer Abogen raises $700m
Suzhou Abogen Biosciences, a Chinese vaccine developer targeting COVID-19, has raised $700 million in Series C funding featuring Temasek Holdings, Loyal Valley Capital, and Lilly Asia Ventures.
Boyu, Janchor back China medical finance start-up
MediTrust Health, China-based healthcare payments and insurance platform, has raised RMB2 billion ($309 million) in Series C funding led by Boyu Capital and Janchor Partners.
Warburg Pincus leads Series C for China AI drug developer
Insilico Medicine, which leverages artificial intelligence (AI) technology to speed up the drug development process, has closed a $255 million Series C funding round led by Warburg Pincus.